Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet

Clinical Cancer Research

Volumn 4, Issue 2, 1998, Pages 349-356

  Kennedy, M John ^a   Zahurak, Marianna L ^a   Donehower, Ross C ^a   Noe, Dennis ^a   Grochow, Louise B ^a   Sartorius, Susan ^a   Chen, Tian Ling ^a   Bowling, Kathy ^a   Duerr, Mary ^a   Rowinsky, Eric K ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; PACLITAXEL;

EID: 0031938204     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Reichman, B. S., Seidman, A. D., Crown, J. P. A., Heelan, R., Hakes, T. B., Lebwohl, D. E., Gilewski, T. A., Surbone, A., Currie, V., Hudis, C. A., Yae, T. J., Klecker, R., Jamis-Dow, C., Collins, J., Quinlivan, S., Berkery, R., Toomasi, F., Canetta, R., Fisherman, J., Arbuck, S., and Norton, L. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J. Clin. Oncol., 11: 1943-1951, 1993.
2. Abrams, J. S., Vena, D. A., Baltz, J., Adams, J., Montello, M., Christian, M., Onetto, N., Sesmond-Hellmann, S., Canetta, R., Friedman, M. A., and Arbuck, S. G. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute treatment referral center trial. J. Clin. Oncol., 13: 2056-2065, 1995.
3. Seidman, A. D., Reichman, B. S., Crown, J. P. A., Yae, T-J., Currie, V., Hakes, T. B., Hudis, C. A., Gilewski, T. A., Baselga, J., Forsythe, P., Lepore, J., Marks, L., Fain, K., Souhrade, M., Onetto, N., Arbuck, S., and Norton, L. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J. Clin. Oncol., 13: 1152-1159, 1995.
4. Sledge, G. W., Neuberg, D., Ingle, J., Martino, S., and Wood, W. Phase III trial of doxorubicin (A) versus paclitaxel (T) versus doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Proc. Am. Soc. Clin. Oncol., 16: 2, 1997.
5. Gelmon, K. A., O'Reilly, S. E., Tolcher, A. W., Campbell, C., Bryce, C., Ragaz, J., Coppin, C., Plenderleith, I. H., Ayers, D., McDermott, B., Nakashima, L., Healey, D., and Onetto, N. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J. Clin. Oncol., 14: 1185-1191, 1996.
6. Sparano, J. A., Neuberg, D., Glick, J. H., Robert, N. J., Goldstein, L. J., Sledge, G. W., and Wood, W. Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study. J. Clin. Oncol., 15: 1880-1884, 1997.
7. Wasserheit, C., Frazien, A., Oratz, R., Sorich, J., and Downey, A., Hochster, H., Chachoua, A., Wernz, J., Zeleniucn-Jacquotte, A., Blum, R., and Speyer, J. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J. Clin. Oncol., 14: 1993-1999, 1996.
8. Tolcher, A. W., Cowan, K. H., Noone, M. H., Denicoff, A. M., Kohler, D. R., Goldspiel, B. R., Barnes, C. S., McCabe, M., Gossard, M. R., Zujewski, J., and O'Shaughnessy, J. A. Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. J. Clin. Oncol., 14: 95-102, 1996.
9. Fennelly, D., Schneider, J., Spriggs, D., Bengala, C., Hakes, T., Reich, L., Barakat, R., Curtin, J., Moore, M. A. S., Hoskins, W., Norton, L., and Crown, J. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J. Clin. Oncol., 13: 1160-1166, 1995.
10. Kennedy, M. J., Zahurak, M. L., Donehower, R. C., Noe, D. A., Sartorius, S., Chen, T-L., Bowling, K., and Rowinsky, E. K. Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony stimulating factor in women with previously treated metastatic breast cancer. J. Clin. Oncol., 14: 783-791, 1996.
11. Holmes, F. A., Madden, T., Newman, R. A., Valero, V., Theriault, R. L., Fraschini, G., Walters, R. S., Booser, D. J., Buzdar, A. U., Willey, J., and Hortobagyi, G. N. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a Phase I study of paclitaxel and doxorubicin inpatients with metastatic breast cancer. J. Clin. Oncol., 14: 2713-2721, 1996.
12. Gianni, L., Munzone, E., Capri, G., Fulfaro, F., Tarenzi, E., Villani, F., Spreadfico, C., Laffranchi, A., Caraceni, A., Martini, C., Stefanelli, M., Valagussa, P., and Bonadonna, G. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J. Clin. Oncol., 13: 2688-2699, 1995.
13. Gianni, L., Viganò, L., Locatelli, A., Capri, G., Giani, A., Tarenzi, E., and Bonadonna, G. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J. Clin. Oncol., 15: 1906-1915, 1997.
14. Chen, T-L., Passos-Coelho, J-L., Noe, D. A., Kennedy, M. J., Black, K. C., Colvin, O. M., and Grochow, L. B. Nonlinear pnarmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplant. Cancer Res., 55: 810-816, 1995.
15. Rowinsky, E. K., Gilbert, M., McGuire, W. P., Noe, D. A., Grochow, L. B., Forastiere, A. A., Ettinger, D. S., Lubejko, B. G., Clark, B., Sartorius, S. E., Cornblath, D. R., Hendricks, C. B., and Donehower, R. C. Sequences of Taxol and cisplatin: a Phase I and pharmacologic study. J. Clin. Oncol., 9: 1692-1703, 1991.
16. LeBlanc, G. A., Sundseth, S. S., Weber, G. F., and Waxman, D. J. Platinum anticancer drugs modulate p-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res., 54: 540-547, 1992.
17. Rowinsky, E. K., Citardi, M. J., Noe, D. A., and Donehower, R. C. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents Taxol and vincristine J. Cancer Res. Clin. Oncol., 119: 727-733, 1993.
18. Liebmann, J. E., Fisher, J., Teague, D., and Cook, J. A. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Oncol. Res., 6: 25-31, 1994.
19. Gehl, J., Boesgaard, M., Paaske, T., Vittrup Jenson, B., and Dombernowsky, P. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann. Oncol., 7: 687-693, 1996.